XML 62 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Discontinued Operations - Schedule of gain from disposal of discontinued operations (Details) - USD ($)
12 Months Ended
Dec. 27, 2023
Dec. 11, 2023
Dec. 31, 2024
Dec. 31, 2023
Discontinued Operations        
Gain on sale of discontinued operations       $ 1,467,451
Discontinued Operations, Disposed of by Sale | Elusys Therapeutics        
Discontinued Operations        
Upfront cash consideration $ 500,000 $ 500,000    
Percentage of gross revenue payable by the Buyer as royalty fee on an annual basis   3.00%    
Threshold aggregate amount of royalty fees that the Company should have received as of December 31, 2028   $ 5,000,000    
Less: net book value of assets and liabilities sold (1,020,549)      
Gain on sale of discontinued operations 1,467,451      
Liabilities assumed $ 51,400,000      
Discontinued Operations, Disposed of by Sale | Elusys Therapeutics | Elusys Therapeutics        
Discontinued Operations        
Shared service fees     $ 191,586 $ 0